JP2010106022A - セルライト及びセルライトに付随する非審美的な外観の低減用の薬剤を含む組成物、及び当該組成物を含む製剤 - Google Patents
セルライト及びセルライトに付随する非審美的な外観の低減用の薬剤を含む組成物、及び当該組成物を含む製剤 Download PDFInfo
- Publication number
- JP2010106022A JP2010106022A JP2009248196A JP2009248196A JP2010106022A JP 2010106022 A JP2010106022 A JP 2010106022A JP 2009248196 A JP2009248196 A JP 2009248196A JP 2009248196 A JP2009248196 A JP 2009248196A JP 2010106022 A JP2010106022 A JP 2010106022A
- Authority
- JP
- Japan
- Prior art keywords
- purity
- cellulite
- composition
- extract
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 208000035484 Cellulite Diseases 0.000 title claims abstract description 49
- 206010049752 Peau d'orange Diseases 0.000 title claims abstract description 49
- 230000036232 cellulite Effects 0.000 title claims abstract description 48
- 239000003814 drug Substances 0.000 title abstract description 5
- 230000003247 decreasing effect Effects 0.000 title abstract 3
- 229940126534 drug product Drugs 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 22
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 19
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 18
- 239000000284 extract Substances 0.000 claims abstract description 16
- 235000010204 pine bark Nutrition 0.000 claims abstract description 12
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 10
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 10
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 31
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims description 29
- 229940108924 conjugated linoleic acid Drugs 0.000 claims description 29
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 25
- 239000011575 calcium Substances 0.000 claims description 25
- 229910052791 calcium Inorganic materials 0.000 claims description 25
- 238000009472 formulation Methods 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 19
- 241000196324 Embryophyta Species 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 12
- 240000006365 Vitis vinifera Species 0.000 claims description 12
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 11
- 239000007903 gelatin capsule Substances 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 235000011609 Pinus massoniana Nutrition 0.000 claims description 7
- 241000018650 Pinus massoniana Species 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 235000015203 fruit juice Nutrition 0.000 claims description 3
- 235000020124 milk-based beverage Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 229910000365 copper sulfate Inorganic materials 0.000 claims description 2
- 229960000355 copper sulfate Drugs 0.000 claims description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229960002849 glucosamine sulfate Drugs 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 2
- 235000005282 vitamin D3 Nutrition 0.000 claims description 2
- 239000011647 vitamin D3 Substances 0.000 claims description 2
- 229940021056 vitamin d3 Drugs 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 229940038487 grape extract Drugs 0.000 claims 2
- 244000052707 Camellia sinensis Species 0.000 claims 1
- 235000006468 Thea sinensis Nutrition 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract 1
- 229940043430 calcium compound Drugs 0.000 abstract 1
- 150000001674 calcium compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 229920002770 condensed tannin Polymers 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 9
- 210000001789 adipocyte Anatomy 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 210000001217 buttock Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940087559 grape seed Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004066 metabolic change Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- GKJZMAHZJGSBKD-ANYPYVPJSA-N 10-trans-12-cis-linoleic acid Natural products CCCCCC=C\C=C\CCCCCCCCC(O)=O GKJZMAHZJGSBKD-ANYPYVPJSA-N 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001633665 Massonia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000567 anti-anemic effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 150000002117 epicatechin derivatives Chemical class 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000001089 mineralizing effect Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940106587 pine bark extract Drugs 0.000 description 1
- 235000020741 pine bark extract Nutrition 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035909 sensory irritation Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000021139 traditional diet Nutrition 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
【解決手段】本発明は、セルライト及びセルライトに付随する非審美的外観の低減のための薬剤を含む相乗組成物であって、共役リノール酸(CLA)、グレープシード抽出物、β-グルカン、有機カルシウム及び松樹皮の乾燥抽出物を、当該マトリクスの相補的相乗薬剤とともに含む組成物を提供することによる。本発明は、このような組成物の使用及び当該組成物を含む製剤にも関する。
【選択図】なし
Description
1−細動脈毛細血管前の括約筋の変化が、血管透過性の変化をもたらし、そして毛細血管の拡張が浮腫をもたらす
2-浮腫が代謝変化を引き起こし、これが網状叢過形成(reticular plexus hyperplasia)及び肥大をもたらし、毛細血管周囲(pericapillarity)形成及び脂肪細胞の沈着をもたらし、そして間質の粘度を増加させる
3-脂肪細胞群の周囲にコラーゲン繊維が組織化し、微小の瘤を形成する
4-最終的に、微小瘤が統合して、大きな瘤を形成し、そして皮膚硬化をもたらす。
a)共役リノール酸(CLA)、グレープシード抽出物、β-グルカン、有機カルシウム及び松樹皮の乾燥抽出物により構成されるベースマトリックス;
b)リボフラビン、葉酸、ビタミンD3、ビオチン、硫酸銅、グルコサミン硫酸及びカメリア・シネシス(Cammellia sinesis)の乾燥抽出物(純度95%)から選ばれるマトリクスの相補的相乗薬剤
を含む組成物である。
共役リノール酸
共役リノール酸(CLA)は、多くの生物学的性質を有し、例えば脂質代謝に対する効果、並びに体及び乳の組成に対する効果を含む。
脂肪細胞における脂肪分解速度を増加させる
分解メカニズム速度を増加させる
食事後に貯蔵される脂肪の量を低下させる
脂肪細胞の合計数を低下させる。
まとめると、これらのメカニズムは、脂肪脂肪の数と大きさの両方を低下させ、そうして脂肪体重を低減する。
乾燥グレープシード抽出物(純度95%)を、治療目的に用いた。当該抽出物は、ポリシアニジン類、アントシアニジン類及びロイコアントシアニジン類(カテキン及びエピカテキン誘導体)に富んでおり、これらはフラボノイドファミリーの両メンバーである。ビチス・ビニフェラの作用は、アンジオテンシンIからIIに変換する酵素を阻害することにより血圧低下を促進し、これは慢性血管機能不全の改善を導くという事実のため生じており、これらは、関連する症状(知覚障害及び疼痛)の改善、及び血管不全に関連する審美的要因の客観的な改善により証拠づけられている。ビチス・ビニフェラは、血小板凝集も低下させ、そしてフリーラジカルのスカベンジング作用のため、特にスーパーオキシド及びヒドロキシルラジカルを補足し、そうして脂質過酸化を阻害することにより、強力な抗酸化作用を発揮する。これらの抗酸化性質は、抗炎症効果及び抗プロテアーゼ能力を増強し、弾性線維を抑制し、そうして内皮細胞の膜を保護する。脂質代謝に関して、抗酸化能力は、高密度リポタンパク質(HDL)血漿濃度を増加させ、総コレステロール及び低密度リポタンパク質(LDL)を低下させる。ビチス・ビニフェラは、抗貧血作用、アルカリ化作用、石灰化(mineralizing)作用、利尿作用、下剤作用、抗炎症作用及び鎮痛作用を有する。
化学的に、β-グルカンは、約1400回の繰り返しユニット、この場合グルコース又はグルコピラノース、密閉構造又は6個の炭素を伴う環、により形成される長い分子-ポリマー-である。単離された場合、熱水中に溶解性の糖であり、透明な溶液を形成し;ほかの分子と相互作用する場合、β−グルカンが、懸濁粒子を形成する。βグルカンは、低い濃度でも、最大で50%血液グルコースレベルを低減することができる。β−グルカンは、ビール酵母の細胞壁から抽出された免疫刺激物質である。β−グルカンは、感染に対する防御に寄与する白血球細胞、例えばマクロファージ、顆粒球、及び単球を活性化し、そして変性組織の修復において役立つ。なぜなら、β−グルカンは、当該再生プロセスを刺激するからである。β-グルカンは、免疫系の調節作用をトリガーし、T及びBリンパ球及びマクロファージ活性を増加させ、ウイルス、細菌、真菌、粒子及び腫瘍細胞感染に対する自然防御を高める多糖類である。
植物起源のカルシウムであり、以下の利点:
・ミネラルの天然ソース
・100%植物由来
・ラクトースフリー
・わずかな香り
・固有の多孔性構造
・ほかのカルシウムソースに比べた場合の優れた感覚刺激性
を有する。
松樹皮は、高い含量のOPC(オリゴマー・プロアンソシアニジン(oligomeric proanthocyanidins))を有する。OPCは、高い抗酸化力を有し、非毒性であり、非変異原性、非発癌性であり、そして副作用は報告されていない。松樹皮の抗酸化能力は、OPCに由来し、ビタミンCの20倍の抗酸化力、そしてビタミンEの50倍の抗酸化力を有する。OPCは、フリーラジカルを中和する抗酸化剤と認められており、OPCは次に、変性疾患及び心臓血管の疾患、目疾患、早期老化において主要な役割を有する。
本発明の製剤は、製品の主要成分、特にマトリクス成分の組み合わせ作用を可能にする。
・食品サプリメント、ソフトゼラチンカプセル
・食品サプリメント、水に溶解させるための溶解性粉末の小袋
・抗セルライト及びスリム化クリーム-化粧品、罹患領域に適用するためのクリームのチューブ
・化粧品、罹患部位にクリームの後に適用されるマッサージオイルのチューブ
マッサージクリーム(1日あたり1,2回)
活性化合物:
共役リノール酸0.5%、グレープシードの標準化抽出物、ビチス・ビニフェラ0.5%、サッカロマイシス・セルビシエのβ-グルカン0.3%、高い生物利用能を有する植物起源の有機カルシウム、AcquaminTG(商標)(リソサムニウム種由来のカルシウム)0.5%、松(パイヌス マッソニアーナ、樹皮の乾燥抽出物)0.5%。
本発明の組成物は、当該集合の単一成分の別々の投与から得られる効果の合計から達成される効果よりもずっと高いセルライト及び関連する非審美的現象の低下を可能にする。これは当該成分間の相乗的効果のためであることが理解される。本発明の組成物は、好ましくは一日2回の用量で主食の際に摂取される。本発明の組成物は、適切な経口投与の形態で剤形されてもよいし、そして医薬技術において広く認められる慣用技術、例えばRemington's Pharmaceutical Handbook、Mack Publishing Co. NY, USAに記載される技術に従って、適切な溶媒賦形剤及びその使用の際に適切な他の共製剤物質(co-formulants)を用いて調製されるであろう。
・ステージ0 立位において、大腿部及び臀部の皮膚がなめらかな表面を有する。つまみ試験を行った際に、でこぼこが存在しない。
・ステージI 立位において、なめらかな皮膚であるが、つまみ試験は膨大及び窪みを示す。
・ステージII 横になった際になめらかな皮膚であるが、立位において変形及び膨大が存在する。この段階は、35/40歳超の女性においてかなり一般的である。
・ステージIII 立位又は横臥位のいずれにかかわらず変形又は膨大の状態が観察される。閉経後の女性及び肥満女性において一般的である。
・セルライト現象の強度を、3ヶ月の治療コースにおいて少なくとも1段階、さらには2段階低下する
・全身脂肪体重を低下させ、そして下半身(脇腹、臀部及び足)並びに腕及び腹部もスリム化する
・大腿部の直径を低減し、そして表皮を調節する
・皮膚の調節と弾力化
を可能にすることが結論づけられた。
・カプセル+ドレーニング剤
・カプセル+マッサージクリーム+マッサージオイル
・カプセル
・ドレーニング剤治療+マッサージクリーム+マッサージオイル
を必要とする。
Claims (8)
- セルライト及びセルライトに付随する非審美的外観を低減するための薬剤を含む組成物であって、当該組成物が以下の:
a) 共役リノール酸(CLA)、グレープシードの抽出物、β-グルカン、有機カルシウム及び松樹皮の乾燥抽出物を含むベースマトリクス;及び
b) 上記マトリクスの追加相乗薬剤であって、リボフラビン、葉酸、ビタミンD3、ビオチン、硫酸銅、グルコサミン硫酸及びカメリア・シネンシス(Camellia sinensis)の乾燥抽出物(純度95%)
を含んでなることを特徴とする、前記組成物。 - 前記マトリクスが、共役リノール酸(純度80%)、標準化グレープ抽出物、ビチス・ビニフェラ(Vitis vinifera)(純度95%)、サッカロマイシス・セルビシエ(Saccharomyces cerevisiae)のβ-グルカン(純度85%)、高い生物利用能を有する植物起源有機カルシウム(リソタムニウム種(Lithothamnium spp.)由来のカルシウム)(純度32%)及び松樹皮(パイヌス・マッソニアナ(Pinus massoniana)の乾燥抽出物(純度95%)を含むことを特徴とする、請求項1に記載の組成物。
- 前記マトリクスが、5〜50%の共役リノール酸(純度80%)、0.5%〜5%標準化グレープシードの抽出物、ビチス・ビニフェラ(Vitis vinifera)(純度95%)、0.2〜2%のサッカロマイシス・セルビシエ(Saccharomyces cerevisiae)(純度85%)のβ-グルカン、3〜30%の高い生物利用能を有する植物由来の有機カルシウム(リソタムニウム種(Lithothamnium spp.)由来のカルシウム)(純度32%)及び0.2〜3%松樹皮(パイヌス・マッソニアナ(Pinus massoniana)の乾燥抽出物を含むことを特徴とする、請求項1又は2に記載の組成物。
- セルライト及びセルライトに付随する非審美的外観の治療用の製剤であって、当該製剤が、請求項1〜3のいずれか一項に記載の組成物を、適切なビヒクル及び賦形剤を伴って含むことを特徴とする、前記製剤。
- 前記製剤が、ソフトゼラチンカプセル、ハードゼラチンカプセル、経口溶液用の小袋、マッサージクリーム及びマッサージオイルの形態で存在することを特徴とする、請求項4に記載の製剤。
- 前記製剤が、100〜2500mgの共役リノール酸(純度80%)、10〜1000mgの標準化グレープシードの抽出物、ビチス・ビニフェラ(Vitis vinifera)(純度95%)、1〜1000mgのサッカロマイシス・セルビシエ(Saccharomyces cerevisiae)のβグルカン(純度85%)、50〜1250mgの高い生物利用能を有する植物起源の有機カルシウム(リソタムニウム種(Lithothamnium spp.)由来のカルシウム)(純度32%)、及び2.5〜500mgの松樹皮(パイヌス・マッソニアナ(Pinus massoniana))(純度95%)の乾燥抽出物を含むことを特徴とする、請求項4又は5に記載の製剤。
- 前記製剤が、250〜1500mgの共役リノール酸(純度80%)、25〜250mgの標準化グレープ抽出物、ビチス・ビニフェラ(Vitis vinifera)(純度95%)、2.5〜50mgのサッカロマイシス・セルビシエ(Saccharomyces cerevisiae)のβ−グルカン(純度85%)、100〜750mgの高い生物利用能を有する植物起源の有機カルシウム(リソタムニウム種(Lithothamnium spp.)由来のカルシウム)(純度32%)、及び5〜250mgの松樹皮の乾燥抽出物(パイヌス・マッソニアナ(Pinus massoniana)(純度95%)を含むことを特徴とする、請求項6に記載の製剤。
- 前記組成物が、セルライト及びセルライトに付随する非審美的外観の治療のための製剤の製造において、そして液体充填システム、ヨーグルト、乳飲料及びフルーツジュースを伴うハードゼラチンカプセルの製造において用いられることを特徴とする、請求項1〜3のいずれか一項に記載の組成物の使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT104241A PT104241B (pt) | 2008-10-29 | 2008-10-29 | Composições incorporando agentes redutores da celulite e inestetismos associados e formulações que as contêm |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010106022A true JP2010106022A (ja) | 2010-05-13 |
Family
ID=41665101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009248196A Pending JP2010106022A (ja) | 2008-10-29 | 2009-10-28 | セルライト及びセルライトに付随する非審美的な外観の低減用の薬剤を含む組成物、及び当該組成物を含む製剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8343557B2 (ja) |
EP (1) | EP2184086A1 (ja) |
JP (1) | JP2010106022A (ja) |
BR (1) | BRPI0904472A2 (ja) |
CA (1) | CA2684157A1 (ja) |
PT (1) | PT104241B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016160181A (ja) * | 2015-02-26 | 2016-09-05 | 株式会社東洋新薬 | 化粧用組成物、美容組成物、関節保護組成物、組成物 |
JP2017508003A (ja) * | 2014-02-11 | 2017-03-23 | イーエルシー マネージメント エルエルシー | ケラチン表面におけるボリュームの外観をモジュレートするための方法、組成物及びキット |
JP2021054770A (ja) * | 2019-09-30 | 2021-04-08 | 株式会社東洋新薬 | 美容組成物 |
JP2022126772A (ja) * | 2019-10-08 | 2022-08-30 | 株式会社東洋新薬 | 美容組成物 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2475934A (en) * | 2009-12-02 | 2011-06-08 | Fit Bioceuticals Pty Ltd | Liquid composition comprising vitamin D |
WO2012022373A1 (de) * | 2010-08-16 | 2012-02-23 | Nutriteam Gmbh | Zweiphasenpräparat sowie dessen verwendung zur behandlung von herpes |
US20130266655A1 (en) * | 2012-04-09 | 2013-10-10 | Phosther Algamar Ltda. | Process for producing a marine mineral concentrate made from lithothamnium seaweed, and the marine mineral concentrate obtained therefrom |
CN102813755B (zh) * | 2012-08-22 | 2015-04-01 | 承德畅达生物科技有限公司 | 防治高脂血症的中药制剂及其制备方法 |
CN103755432A (zh) * | 2013-11-25 | 2014-04-30 | 太仓立成再生能源有限公司 | 以松树皮为原料生产的有机基质及其生产工艺 |
EP3122559B1 (en) | 2014-03-25 | 2021-11-24 | 3D Systems, Inc. | Methods, devices, and systems for the fabrication of materials and tissues utilizing electromagnetic radiation |
KR102133218B1 (ko) * | 2017-09-19 | 2020-07-13 | (주)큐젠바이오텍 | 체지방 감소 보조제 및 베타글루칸을 유효성분으로 하는 비만 예방 또는 치료용 조성물 |
IT201900022764A1 (it) * | 2019-12-03 | 2021-06-03 | Skb Llc | Prodotto per la cura della pelle e procedimento per la sua realizzazione |
CN110923254B (zh) * | 2019-12-09 | 2021-04-16 | 中国林业科学研究院亚热带林业研究所 | 马尾松长叶烯合成酶基因和产品及用途 |
FR3120188B3 (fr) * | 2021-02-26 | 2023-09-22 | Activinside | Composition comprenant un extrait deVitis vinifera, de la vitamine C et des probiotiques pour lutter contre le vieillissement de la peau |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003507400A (ja) * | 1999-08-20 | 2003-02-25 | ハワード ムラード | セリュライトの出現を軽減する医薬組成物及び方法 |
JP2003508479A (ja) * | 1999-09-09 | 2003-03-04 | ペンタファルム・リミテッド | セルライトの局所治療のための共役化リノール酸(cla)の使用 |
US20050260285A1 (en) * | 2004-05-21 | 2005-11-24 | Dimateeo-Leggio Giovina | Healthy prostate formula |
JP2007505850A (ja) * | 2003-09-19 | 2007-03-15 | インデナ エッセ ピ ア | セルライト治療のための経口組成物 |
WO2008047061A2 (fr) * | 2006-10-20 | 2008-04-24 | Laboratoires Inneov | Utilisation cosmetique par voie orale et/ou parenterale de la glucosamine eventuellement associee a au moins un compose polyphenol et composition correspondante |
EP2008662A1 (en) * | 2006-04-07 | 2008-12-31 | Kao Corporation | Lypolysis promoter |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2674126B1 (fr) * | 1991-03-19 | 1995-03-10 | Secma | Utilisation d'algues rouges calcaires pour la preparation de compositions cosmetiques. |
JPH1171294A (ja) * | 1997-08-29 | 1999-03-16 | Pias Arise Kk | コラゲナーゼ阻害剤 |
AU3657100A (en) * | 1999-03-12 | 2000-10-04 | Biotec Asa | Use of water-soluble beta-(1,3) glucans as agents for producing therapeutic skintreatment agents |
US20010041708A1 (en) | 2000-02-15 | 2001-11-15 | Zen-Bio, Inc. | Compositions for preventing cellulite in mammalian skin |
WO2003006009A1 (en) | 2001-07-11 | 2003-01-23 | Zen-Bio, Inc. | Compositions for reducing or preventing cellulite in mammalian skin |
JP4796734B2 (ja) * | 2002-03-19 | 2011-10-19 | 株式会社ディーエイチシー | マトリックスメタロプロテアーゼ活性阻害剤 |
KR100873059B1 (ko) * | 2002-07-18 | 2008-12-09 | 주식회사 더멋진 바이오텍 | 베타글루칸의 지방축적 억제 용도 |
-
2008
- 2008-10-29 PT PT104241A patent/PT104241B/pt not_active IP Right Cessation
-
2009
- 2009-10-23 EP EP09398012A patent/EP2184086A1/en not_active Ceased
- 2009-10-27 US US12/606,700 patent/US8343557B2/en not_active Expired - Fee Related
- 2009-10-28 JP JP2009248196A patent/JP2010106022A/ja active Pending
- 2009-10-29 BR BRPI0904472-8A patent/BRPI0904472A2/pt not_active Application Discontinuation
- 2009-10-29 CA CA2684157A patent/CA2684157A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003507400A (ja) * | 1999-08-20 | 2003-02-25 | ハワード ムラード | セリュライトの出現を軽減する医薬組成物及び方法 |
JP2003508479A (ja) * | 1999-09-09 | 2003-03-04 | ペンタファルム・リミテッド | セルライトの局所治療のための共役化リノール酸(cla)の使用 |
JP2007505850A (ja) * | 2003-09-19 | 2007-03-15 | インデナ エッセ ピ ア | セルライト治療のための経口組成物 |
US20050260285A1 (en) * | 2004-05-21 | 2005-11-24 | Dimateeo-Leggio Giovina | Healthy prostate formula |
EP2008662A1 (en) * | 2006-04-07 | 2008-12-31 | Kao Corporation | Lypolysis promoter |
WO2008047061A2 (fr) * | 2006-10-20 | 2008-04-24 | Laboratoires Inneov | Utilisation cosmetique par voie orale et/ou parenterale de la glucosamine eventuellement associee a au moins un compose polyphenol et composition correspondante |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017508003A (ja) * | 2014-02-11 | 2017-03-23 | イーエルシー マネージメント エルエルシー | ケラチン表面におけるボリュームの外観をモジュレートするための方法、組成物及びキット |
JP2016160181A (ja) * | 2015-02-26 | 2016-09-05 | 株式会社東洋新薬 | 化粧用組成物、美容組成物、関節保護組成物、組成物 |
JP2021054770A (ja) * | 2019-09-30 | 2021-04-08 | 株式会社東洋新薬 | 美容組成物 |
JP7424606B2 (ja) | 2019-09-30 | 2024-01-30 | 株式会社東洋新薬 | 美容組成物 |
JP2022126772A (ja) * | 2019-10-08 | 2022-08-30 | 株式会社東洋新薬 | 美容組成物 |
Also Published As
Publication number | Publication date |
---|---|
US8343557B2 (en) | 2013-01-01 |
CA2684157A1 (en) | 2010-04-29 |
PT104241A (pt) | 2010-04-29 |
US20100278908A1 (en) | 2010-11-04 |
PT104241B (pt) | 2012-03-06 |
BRPI0904472A2 (pt) | 2010-11-16 |
EP2184086A1 (en) | 2010-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010106022A (ja) | セルライト及びセルライトに付随する非審美的な外観の低減用の薬剤を含む組成物、及び当該組成物を含む製剤 | |
EP1427297B1 (en) | Composition for reducing appetite in mammals comprising procyanidin | |
US20090110674A1 (en) | Health supplement | |
CA2563952C (en) | Uses of the pregnane glycosides in the treatment/management of obesity, obesity-related and other disorders | |
AU776037B2 (en) | An anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems | |
CN105232907A (zh) | 一种补肾壮阳饮料及其制备方法 | |
RU2489934C2 (ru) | Способ производства биологически активных продуктов из бурых водорослей и плодов | |
JP2010159283A (ja) | プロアントシアニジン含有組成物 | |
US20050142235A1 (en) | Composition comprising an aqueous extract of red vine leaves and an antithrombotic agent | |
WO2012063198A1 (en) | Compositions for the prevention and treatment of erectile dysfunction and impotence and for improving sport performance | |
US20060135444A1 (en) | Combination of flavonoid and procyanidin for the reduction of the mammalian appetite | |
JP2011195534A (ja) | ヒアルロン酸産生促進剤、抗老化剤およびしわ改善剤 | |
CN102771794A (zh) | 一种沙棘油维生素ec软胶囊 | |
KR100532556B1 (ko) | 솔잎, 녹차 및 홍차 추출물을 유효성분으로 함유하는 비만및 변비 치료용 조성물 | |
CN117100756A (zh) | 叶绿酸组合物和其用途 | |
CN110859912A (zh) | 一种用于前列腺炎的中药组合物及其制备方法和应用 | |
WO2017039716A1 (en) | Nutraceutical composition and method of use thereof | |
Fatima et al. | Nutraceutical and Nanonutraceutical in the Management of CVD and Hypertension | |
CN115607635B (zh) | 一种灵芝复方制剂及其制备方法和应用 | |
IT202100015446A1 (it) | Formulazione a base di estratto Cranberry, Uva Ursina, ed un terzo estratto | |
RU2571287C1 (ru) | Средство для эндоэкологической реабилитации | |
WO2022259195A1 (en) | Oral composition for the treatment and/or prevention of disorders associated with menopause. | |
WO2020152131A1 (en) | Olive fruit extract suitable for reducing body-mass index and visceral fat in overweight subjects | |
WO2006067866A1 (ja) | プロアントシアニジン含有組成物 | |
Simons | Treating Disorders in a Natural Manner: Applications from acne and allergy to varicose veins and weight reduction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140128 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140425 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140501 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140728 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140819 |